2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Strober B, Thaçi D, Sofen H, Kircik L, Gordon K, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp K. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Journal Of The American Academy Of Dermatology 2022, 88: 40-51. PMID: 36115523, DOI: 10.1016/j.jaad.2022.08.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalDermatologic AgentsDouble-Blind MethodHumansPsoriasisSeverity of Illness IndexTreatment OutcomeTYK2 KinaseConceptsGlobal assessment scoreSevere plaque psoriasisStatic Physician's Global Assessment scorePhysician Global Assessment scorePlaque psoriasisAdverse eventsPsoriasis AreaWeek 16Assessment scoresFrequent adverse eventsPhase 3 trialSerious adverse eventsSeverity IndexPhase 3 programSecond trialApremilast patientsWeek 52Laboratory parametersPsoriasis pathogenesisSafety resultsPlaceboDeucravacitinibStudy durationPsoriasisPatientsDeucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Armstrong A, Gooderham M, Warren R, Papp K, Strober B, Thaçi D, Morita A, Szepietowski J, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Journal Of The American Academy Of Dermatology 2022, 88: 29-39. PMID: 35820547, DOI: 10.1016/j.jaad.2022.07.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodHumansPsoriasisSeverity of Illness IndexTreatment OutcomeConceptsSevere plaque psoriasisGlobal assessment scorePlaque psoriasisWeek 16Static Physician's Global Assessment scoreResponse ratePhysician Global Assessment scoreCoprimary end pointsAdverse event ratesOne-year durationPASI 75Psoriasis AreaWeek 52Psoriasis treatmentPlaceboSafety resultsDeucravacitinibApremilastEnd pointEvent ratesAssessment scoresPsoriasisSeverity IndexKinase 2 inhibitorTyrosine kinase 2 inhibitor
2021
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. New England Journal Of Medicine 2021, 385: 2219-2229. PMID: 34879448, DOI: 10.1056/nejmoa2103629.Peer-Reviewed Original ResearchConceptsPrimary end pointPatient-reported outcomesTapinarof creamGlobal assessment scoreBody surface areaPlaque psoriasisWeek 12End pointPGA responseAdverse eventsPGA scoreMean changeSkin barrier protein filaggrinSecondary efficacy end pointsUpper respiratory tract infectionPhysician Global Assessment scoreNumeric rating scale scoreTotal body surface areaTotal scoreEfficacy end pointIdentical phase 3Local adverse eventsSymptom diary scoresProportion of patientsSecondary end pointsEfficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
Van Voorhees A, Gold L, Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. British Journal Of Dermatology 2021, 185: 840-842. PMID: 33763874, PMCID: PMC8518877, DOI: 10.1111/bjd.20083.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodHumansPsoriasisScalpSeverity of Illness IndexThalidomideTreatment Outcome
2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Van Voorhees A, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Journal Of The American Academy Of Dermatology 2020, 83: 96-103. PMID: 32032692, DOI: 10.1016/j.jaad.2020.01.072.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodDrug Administration ScheduleFemaleHumansMalePsoriasisQuality of LifeScalp DermatosesSeverity of Illness IndexThalidomideTreatment OutcomeConceptsSevere scalp psoriasisNumeric rating scaleItch Numeric Rating ScaleDermatology Life Quality IndexSafety of apremilastScalp psoriasisPhase 3bWeek 16Inadequate response/intolerancePhysician Global Assessment responseCommon adverse eventsPhysician global assessmentPlacebo-controlled studySevere plaque psoriasisDouble-blind studyProportion of patientsLife Quality IndexPruritic areaPlaque psoriasisPrimary endpointSecondary endpointsAdverse eventsMore patientsMild diseasePsoriasis therapy
2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Journal Of Dermatological Science 2019, 96: 126-133. PMID: 31787506, DOI: 10.1016/j.jdermsci.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdipokinesAdultAgedAnti-Inflammatory Agents, Non-SteroidalApolipoproteinsCytokinesDouble-Blind MethodFemaleHumansMaleMiddle AgedPsoriasisT-Lymphocyte SubsetsThalidomideConceptsModerate plaque psoriasisIL-17APlaque psoriasisIL-22Week 16T cellsRegulatory T cell numbersT helper 17 (Th17) cellsEfficacy of apremilastIL-23 levelsTotal T cellsPlasma cytokine levelsRegulatory T cellsT cell numbersMedian percentage reductionPathogenesis of psoriasisSevere psoriasisCardiometabolic biomarkersClinical improvementCytokine levelsInflammatory biomarkersIL-17FWeeks 0Clinical trialsWeek 4
2017
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Strober B, Karki C, Mason M, Guo N, Holmgren S, Greenberg J, Lebwohl M. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2017, 78: 323-332. PMID: 29051036, DOI: 10.1016/j.jaad.2017.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalBiological ProductsBody Surface AreaComorbidityCost of IllnessCross-Sectional StudiesFatigueFemaleHumansInterleukin-12Interleukin-17Interleukin-23MaleMiddle AgedPainPatient Reported Outcome MeasuresProspective StudiesPsoriasisQuality of LifeRegistriesSeverity of Illness IndexThalidomideTumor Necrosis Factor-alphaUnited StatesConceptsCorrona Psoriasis RegistryPsoriasis RegistryDisease durationComparative safetyBody surface area involvementTumor necrosis factor inhibitorsIL-12/23 inhibitorsInterleukin-17A inhibitorInvestigator's Global AssessmentNecrosis factor inhibitorsSurface area involvementLonger disease durationCross-sectional studyLong-term safetyEfficacy of treatmentPsoriatic arthritis diagnosisQuality of lifeEfficacy of foodMultiple comorbiditiesRegistry cohortSystemic medicationsSystemic therapyFactor inhibitorsArea involvementBiologic treatmentEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Journal Of Drugs In Dermatology 2017, 16: 801-808. PMID: 28809995.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodFemaleHumansMaleMiddle AgedPsoriasisQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesSymptom AssessmentThalidomideUnited StatesConceptsModerate plaque psoriasisSafety of apremilastPlaque psoriasisGlobal assessment scoreStatic Physician's Global Assessment scoreDermatology Life Quality Index scoresUpper respiratory tract infectionPhysician Global Assessment scoreLife Quality Index scoresPercentage changePrior topical therapyMost adverse eventsPrimary efficacy endpointSevere plaque psoriasisTreatment Satisfaction QuestionnaireRespiratory tract infectionsHigh patient satisfactionMean percentage changeQuality Index scoresQuality of lifeGreater percentage changeEfficacy endpointAdverse eventsTopical therapyTract infections
2015
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald J, Klufas D, Strober B. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. Journal Of Drugs In Dermatology 2015, 14: 888-92. PMID: 26267735.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCyclosporineDermatologic AgentsDrug Therapy, CombinationEtanerceptFemaleFoot DermatosesHand DermatosesHumansImmunosuppressive AgentsInfliximabMaleMethotrexateMiddle AgedMycophenolic AcidPsoriasisSeverity of Illness IndexThalidomideUstekinumabYoung AdultCurrent and Future Oral Systemic Therapies for Psoriasis
Kelly J, Foley P, Strober B. Current and Future Oral Systemic Therapies for Psoriasis. Dermatologic Clinics 2015, 33: 91-109. PMID: 25412786, DOI: 10.1016/j.det.2014.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAnti-Inflammatory Agents, Non-SteroidalAntimetabolitesCyclosporineFumaratesHumansHydroxyureaImmunosuppressive AgentsIsoxazolesKeratolytic AgentsLeflunomideMethotrexateMycophenolic AcidPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesSulfasalazineThalidomideThioguanine
2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
Leonardi C, Strober B, Gottlieb A, Elewski B, Ortonne J, van de Kerkhof P, Chiou C, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. Journal Of Drugs In Dermatology 2010, 9: 928-37. PMID: 20684143.Peer-Reviewed Original ResearchConceptsLong-term safetyExtension studyOpen-label etanercept treatmentPrevious phase 3 studyOpen-label extension studyEfficacy of etanerceptOpen-label studySevere plaque psoriasisPhase 3 studySymptoms of psoriasisEligible patientsEtanercept treatmentInterrupted therapySubcutaneous etanerceptEtanercept therapyPlaque psoriasisAdverse eventsPsoriatic patientsEtanerceptPatientsSkin diseasesPsoriasisWeeksYears of experiencePredetermined criteria
2008
Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis
Strober B, Teller C, Yamauchi P, Miller J, Hooper M, Yang Y, Dann F. Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal Of Dermatology 2008, 159: 322-330. PMID: 18503600, DOI: 10.1111/j.1365-2133.2008.08628.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticBiomarkersBody Mass IndexC-Reactive ProteinDouble-Blind MethodEtanerceptFemaleHumansImmunoglobulin GMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRetrospective StudiesSeverity of Illness IndexTumor Necrosis Factor-alphaConceptsC-reactive proteinBody mass indexEffect of etanerceptCRP levelsPsoriatic arthritisCRP valuesBaseline C-reactive proteinC-reactive protein levelsHigher body mass indexLower body mass indexBaseline CRP valuesBaseline PASI scoreSkin disease activityStatin drug useSevere plaque psoriasisBaseline CRP levelsElevated CRP levelsSeverity Index scoreEtanercept treatmentRegistrational studiesCRP elevationPlaque psoriasisCardiovascular riskDisease activityPASI score
2006
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis
Elewski B, Leonardi C, Gottlieb A, Strober B, Simiens M, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. British Journal Of Dermatology 2006, 156: 138-142. PMID: 17199580, DOI: 10.1111/j.1365-2133.2006.07585.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleEtanerceptHumansImmunoglobulin GPsoriasisReceptors, Tumor Necrosis FactorSeverity of Illness IndexTreatment OutcomeConceptsPhase 3 studyWeeks of etanerceptGlobal phase 3 studyExtension study baselineExtension studyPK profilesEfficacy endpointStudy baselinePharmacokinetic profileTumor necrosis factor antagonistsOpen-label extension studyDermatology Life Quality IndexGlobal assessmentMean PASI scoreNew safety findingsNecrosis factor antagonistsPhysician global assessmentSevere plaque psoriasisSubset of patientsLife Quality IndexSet of patientsPlaque psoriasisAdult patientsPASI scorePsoriasis Area
2004
Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober B, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Journal Of Drugs In Dermatology 2004, 3: 270-2. PMID: 15176161.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticCyclosporineDose-Response Relationship, DrugDrug Therapy, CombinationEtanerceptFemaleHumansImmunoglobulin GKeratolytic AgentsMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRecombinant Fusion ProteinsConceptsTumor necrosis factorTumor necrosis factor receptorWeekly doseRheumatoid arthritisPatients of psoriasisPlacebo-controlled studySevere plaque psoriasisSelf-administered medicationsJuvenile rheumatoid arthritisTreatment of psoriasisHuman fusion proteinNecrosis factor receptorPlaque psoriasisContinuous therapyPsoriasis AreaPsoriatic arthritisSystemic therapyPsoriasis patientsTreatment regimenClinical efficacyCombination therapyMedical historyClinical trialsNecrosis factorEtanercept
2001
Lupus panniculitis (lupus profundus).
Strober B. Lupus panniculitis (lupus profundus). Dermatology Online Journal 2001, 7: 20. PMID: 12165236, DOI: 10.5070/d38f30c7rd.Peer-Reviewed Original Research